It is provided pursuant to the US Food and Drug Administration (FDA) guidance that immunoassays for COVID-19 are less complex than molecular assays, and therefore notification is sufficient to be performed by a high complexity laboratory. Pertinent information for COVID-19 antibody tests that have not been FDA reviewed:
Market Data 
Markets 
AI
